PriceSensitive

Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psychedelics
CSE:PSYC
19 October 2021 15:00 (EDT)

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.

Preliminary data that has been generated in tests done by the National Research Council of Canada (NRC) shows that AME-1 extract can inhibit human connective-tissue mast cell activation.

Mast cells are important inflammatory cells present in the skin, gut, brain, and lungs. When activated, these cells release pro-inflammatory mediators such as histamine and cytokines, contributing to inflammatory diseases such as atopic dermatitis and urticaria, also known as hives, in the skin.

The results of the studies show that pre-treatment of human mast cells with AME-1 extract inhibited their activation and partially blocked the release of proinflammatory mediators.

This preliminary evidence suggests a potential key nutritional systematic and functional property of AME-1, with research continuing to further examine the mechanisms of this inhibition.

Brian Tancowny, Scientific Advisor to Psyched, said: “The first set of preliminary evidence in this investigative study of AME-1 reveals the discovery of a novel health and wellness benefit, as well as a new functional property.”

“It is very inspiring to have found an additional functional immune property of AME-1, and further work is being done to investigate this possibility, as well as potential neuroprotective properties of AME-1,” added Tancowny.

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

Psyched Wellness Ltd. (PSYC) is up 10 per cent, trading at C$0.16 at 2:23 pm ET.

Related News